Today, CHAILEEDO has learned that Jiangsu Jiangshan Jland Biotech Co., Ltd. (hereinafter referred to as “Jland Biotech”) has recently completed a financing round exceeding 100 million RMB. This round of financing was jointly invested by SDIC Venture Capital and Yuexiu Industrial Fund. The funds will support Jland Biotech in strengthening its strategic positioning in the field of biosynthesis, comprehensively enhancing its competitiveness as a global leading synthetic biology functional protein “intelligent manufacturing platform.”
Specifically, this round of financing by Jland Biotech will mainly be used in the following three areas. First, to increase production capacity and automation: expanding and upgrading its biomanufacturing “super factory” to build an intelligent protein production platform.
Second, to enhance raw material R&D and application innovation: continuing to expand the functional development of collagen in areas such as medical devices and tissue engineering.
Third, to expand global markets and brand presence: promoting international registration and compliance, and using high-quality recombinant collagen raw materials to deeply empower major global pharmaceutical, health, and beauty brands, further expanding into global markets including North America, Europe, and Southeast Asia.
Regarding this round of financing, Jland Biotech Chairman Chang Liang stated, “This round of financing is a strong recognition by the market of Jland Biotech’s technology platform and business model. We will continue to make breakthroughs in green biomanufacturing, product and technological innovation, structural optimization, and scenario expansion, allowing the next generation of collagen to serve global consumers and industry clients in a more sustainable and higher-performing way.”
Public information shows that Jland Biotech focuses on the R&D and production of recombinant collagen and multi-type functional proteins driven by synthetic biology. Since the launch of its first recombinant Type V collagen product in 2024, Jland Biotech has built a diverse product matrix covering Type I, III, IV, V, VII, XVII, fibronectin, elastin, and other types of collagen, achieving deep applications in cosmetics, medical devices, and food nutrition fields. It has become one of the world’s largest and most diverse recombinant collagen suppliers.
In terms of financing, public information shows that Jland Biotech previously completed two financing rounds. The earliest was in June 2021, when Jland Biotech completed a Series A round raising tens of millions of RMB, with Yida Capital as the investor. In September 2023, Jland Biotech completed a Series B round, led by Qianji Capital, with co-investment from German specialty chemicals company Evonik through its venture capital division.
